LPCN News Alert Lipocine Inc (LPCN) 5.91 02/13/2015 22:35:47

New Post Public Reply Private Reply Replies (0) Message Board

Feb 13, 2015 at 11:35 PM

Lipocine Inc (LPCN) 5.91 $LPCN

Nasdaq stocks posting largest percentage increases
AP - Fri Feb 13, 12:23PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
CYTK: 7.78 (+1.29), ADHD: 6.92 (+0.73), RCKY: 18.43 (+4.33), LPCN: 5.91 (+0.40), COLM: 51.50 (+7.91)

Lipocine Announces Presentation of LPCN 1107 Clinical Data at the Society for Maternal-Fetal Medicine 35th Annual Meeting
GlobeNewswire - Fri Jan 30, 9:39AM CST
Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced that data from a successful Phase 1 study of LPCN 1107, the company's oral hydroxyprogesterone caproate ("HPC"

product candidate will be presented at the Society for Maternal-Fetal Medicine 35 Annual Meeting in San Diego, CA. The study was designed to determine the pharmacokinetics and bioavailability of LPCN 1107 relative to an intramuscular (IM) HPC, as well as safety and tolerability, in healthy non-pregnant female volunteers.
LPCN: 5.91 (+0.40)

Lipocine Inc. (Nasdaq: LPCN) to Ring The Nasdaq Stock Market Closing Bell
GlobeNewswire - Fri Jan 16, 9:00AM CST
What:
LPCN: 5.91 (+0.40), NDAQ: 49.48 (-0.27)

Lipocine Continues To Generate Positive Data
David Bautz - at Seeking Alpha - Wed Jan 14, 5:45PM CST

LPCN: 5.91 (+0.40)

Lipocine Announces Positive Phase 1b Top-Line Results With LPCN 1107 in Pregnant Women
GlobeNewswire - Mon Jan 12, 8:15AM CST
-- First demonstration of relevant hydroxyprogesterone caproate levels following oral administration in pregnant women
LPCN: 5.91 (+0.40)

15 Biotech Names For 2015
Jason Napodano, CFA - at Seeking Alpha - Mon Jan 05, 1:37PM CST

NBIX: 37.22 (+0.27), LPCN: 5.91 (+0.40), EPRS: 7.67 (+0.67), DEPO: 18.38 (+0.20), ASPX: 65.76 (+2.76), BCLI: 3.86 (-0.02), CUR: 3.41 (+0.13)

FDA Confirms Lipocine's Previously-Agreed Clinical Development Plan for LPCN 1021
GlobeNewswire - Mon Dec 15, 8:05AM CST
Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced that it has received confirmation from the U.S. Food and Drug Administration ("FDA"

that the design of its ongoing pivotal Study of Oral Androgen Replacement ("SOAR"

Phase 3 clinical study (http://clinicaltrials.gov/show/NCT02081300) evaluating efficacy and safety of LPCN 1021 in hypogonadal men with low testosterone ("Low T"

is currently acceptable for filing a New Drug Application ("NDA"

for the class testosterone replacement therapy ("TRT"

labeling. The FDA reiterated the primary efficacy endpoint required for approval being 75% of subjects with a Cavg for serum testosterone in the normal range with the lower bound of the two-sided 95% confidence interval being >65%. Lipocine remains confident that our efficacy results are in line with approval requirements.
LPCN: 5.91 (+0.40)

Lipocine to Present at the Piper Jaffray 26th Annual Healthcare Conference
GlobeNewswire - Tue Nov 25, 7:07AM CST
Lipocine Inc.(Nasdaq:LPCN), a specialty pharmaceutical company, today announced Mahesh Patel, President and CEO, and Morgan Brown, Executive Vice President and CFO, will present a company overview at the Piper Jaffray 26th Annual Healthcare Conference on Tuesday, December 2, 2014 at 2:30 p.m. ET.
LPCN: 5.91 (+0.40)

Lipocine Announces Management Changes
GlobeNewswire - Mon Nov 17, 7:18AM CST
Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced changes to its executive management team. Changes include the departures of Dr. Srinivasan Venkateshwaran, Chief Technology Officer and Vice President Research & Development, effective November 14, 2014 and Mr. Gerald Simmons, Chief Business Development Officer, effective November 28, 2014. The Company has an ongoing search for a Chief Medical Officer and a Vice President of Business Development and Commercial.
LPCN: 5.91 (+0.40)

Lipocine axes two execs
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 6:58PM CST

LPCN: 5.91 (+0.40)

Lipocine Announces Financial and Operational Results for the Third Quarter of 2014
GlobeNewswire - Mon Nov 10, 7:42AM CST
Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced financial results for the quarter ended September 30, 2014, as well as recent operational highlights.
LPCN: 5.91 (+0.40)

Lipocine beats by $0.23
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 7:19AM CST

LPCN: 5.91 (+0.40)

Lipocine Announces Positive Top-Line Results in Phase 2a Study of LPCN 1111
GlobeNewswire - Mon Oct 13, 6:09AM CDT
Candidate For Once Daily Dosing
LPCN: 5.91 (+0.40)

IPOs and Transactions Week in Review: September 29 - October 3
PR Newswire - Mon Oct 06, 1:25PM CDT
Vintage, the capital markets division of PR Newswire, has released its weekly IPO and Transaction summary.
RCAP: 10.28 (+0.28), CPTA: 18.72 (-0.03), PTN: 0.72 (-0.02), LPCN: 5.91 (+0.40), XGTI: 0.43 (+0.01), ENRJ: 2.81 (+0.06), SINO: 1.50 (unch)

SOXX, XONE, LPCN, Added To Naked Short Lists Today
M2 - Mon Oct 06, 9:30AM CDT
BUYINS.NET, www.buyins.net , announced today that these select companies have been Added To the NASDAQ, AMEX, NYSE, OTCBB and Pinksheet naked short threshold lists. iShares PHLX SOX Semiconductor Sector Index Fund (NASDAQ:SOXX), (NASDAQ:XONE), (NASDAQ:LPCN). For a complete list of companies on the naked short lists please visit our web site. To find the SqueezeTrigger Price before a short squeeze starts in any stock, go to http://www.buyins.net .
XONE: 16.93 (-0.16), LPCN: 5.91 (+0.40), SOXX: 95.43 (+0.67)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ford Foundation Welcomes Gender Justice Leader Fatima Goss Graves

A Fresh Addition to Ford's Trustees Fatima Goss Graves steps into big shoes at the Ford Foundation as she gets appointed to its Board of Trustees. No small potatoes, this move suggests the Foundation's commitment to driving significant gender justice and advocacy. Add her name next to serious change-makers, folks, because Ms. Goss Graves is a heavyweight in the nonprofit...

Coastal Financial Faces Lawsuit Over Fraud Allegations

Coastal Financial Corporation, riding high on NASDAQ as CCB, now finds itself in the middle of a storm. Schall, Brown & Schwartz LLP, a firm known for its shareholder rights litigation, has thrown the gauntlet with a class action lawsuit against Coastal for suspected securities violations. We're talking about potential fibs under Section 10(b) and 20(a) of the Securities...

Moore Law Urges Millrose Investors: Join the Action

Is Millrose Playing a Risky Game? When I caught wind of this latest debacle with Millrose Properties, Inc. (NYSE: MRP), my gut reaction was a mix of curiosity and skepticism. Hunterbrook Media's report just blasted across the headlines, digging up some dirt on Millrose's recent financial maneuvers. Apparently, these cats have been busy buying homes to the tune of $200...

Ruth E. Carter Returns Home with Celebrated Exhibition

Ruth E. Carter’s Triumphant Return When a titan of the costume design world circles back to their roots, you know it’s bound to be something special. Ruth E. Carter, who has swapped needles and threads for Oscars (twice, mind you), is making a return to Hampton University, paying homage to the very soil that sowed her artistic seeds. Ain't that a capstone of a career...

PrePass Intelligence: A Game-Changer for Fleets

Picture this: you're at the wheel of a beastly 18-wheeler, barreling down the highway and skipping weigh stations thanks to PrePass. But here’s where the real magic kicks in. PrePass Intelligence just rolled out, aiming to squeeze every last drop of value from bypass and toll data. That's cold hard cash for fleet operators who can finally make sense of these fleeting...

Ball Corp's Leadership Shuffle Aims for Strategic Gains

Leadership Changes in the Midst of Market Challenges You don't need a crystal ball to see that leadership changes can signal either turmoil or opportunity. Ball Corporation, a titan in the realm of aluminum packaging, is experiencing a shake-up at the top of its beverage packaging business units. With Carey Causey stepping into the role for North and Central America, and...

Art Print Paper: Finding the Perfect Match for Masterpieces

You ever stand in a gallery and notice how some art just lights up the room while others barely get a second glance? Well, a lot of that magic starts with an unsung hero—paper choice. I came across this bit from HelloNation diving into what makes paper selection a cornerstone for fine art prints. Now, I ain't an artist, but even a bruiser trader like me can see the...

QFIN Faces Class Action: Investors' Role Explored

Cracks in the Facade: QFIN's Legal Mess You're cruising down the usual market lanes when—bam!—news breaks that Qfin Holdings, Inc. (NASDAQ: QFIN) finds itself hip-deep in a class action lawsuit. Seems like our pals at Schall, Brown & Schwartz LLP have thrown the gauntlet down, with claims of some serious smoke and mirrors during the March to August stretch of 2026....

Spooky Suds: House of Horror Meets El Car Wash

A Haunted Wash Awaits Miami Drivers Picture this: you're cruising down West Flagler on a regular Wednesday evening, but tonight, you're not just rolling in for a rinse. Nope, this Wednesday night, the wash tunnel at El Car Wash gets downright spooky. It's getting a haunted house makeover with scare actors from the House of Horror. When a Car Wash Becomes a Haunted...

OppFi Readies Q3 Earnings; Investors Eye Financials

What's Unfolding at OppFi? Mark your calendars, folks. October 28th is the day OppFi (NYSE: OPFI) pulls the curtain back on its third-quarter 2026 earnings. For the uninitiated, we're talking about a tech-driven finance platform that's been making waves by providing financial solutions for everyday Americans. And you bet we're all ears for what those numbers say. Details...